- Home
- FTHM vs QNRX Comparison
FTHM vs QNRX Comparison
Compare FTHM & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTHM | QNRX |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4M | 9.2M |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | FTHM | QNRX |
|---|---|---|
| Price | $0.18 | $4.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $20.38 |
| AVG Volume (30 Days) | ★ 449.9K | 23.2K |
| Earning Date | 11-17-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $420,477,000.00 | N/A |
| Revenue This Year | $9.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.45 | N/A |
| 52 Week Low | $0.17 | $3.25 |
| 52 Week High | $1.52 | $23.50 |
Technical Indicators
Market Signals| Indicator | FTHM | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 28.19 | 42.41 |
| Support Level | N/A | $4.03 |
| Resistance Level | $0.92 | $4.50 |
| Average True Range (ATR) | 0.02 | 0.26 |
| MACD | 0.02 | 0.09 |
| Stochastic Oscillator | 34.00 | 41.33 |
Price Performance
Historical ComparisonAbout FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, and Software as a Service (SaaS) offerings to brokerages and agents by leveraging intelliAgent , proprietary cloud-based software. The Company's three operating and reportable segments: Real Estate Brokerage, Mortgage, and Title. The majority of revenue is from Real Estate Brokerage, which provides real estate brokerage services.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.